CAMP Form 3: Dr. Tardiff Discloses 74,578 Stock Options
Rhea-AI Filing Summary
Initial Form 3 filing shows Dr. Daniel Tardiff, Chief Scientific Officer and director at Camp4 Therapeutics (CAMP), reporting ownership entirely through stock options. He holds options covering 74,578 shares of common stock with exercise prices of $9.08, $3.86, and $3.53. Vesting schedules start on 09/18/2023 and 04/01/2025
Positive
- Substantial option holdings: 74,578 options align officer incentives with shareholders
- Clear vesting schedules: 25% cliff and monthly vesting provide retention alignment
Negative
- No reported direct common stock ownership: economic exposure depends on exercising options
- Exercise prices vary: portions priced at $9.08 may be out-of-the-money depending on market price
Insights
Officer reports only option-based ownership totaling 74,578 shares.
The reporting shows no direct common stock holdings; all beneficial ownership is via four stock options with exercise prices of $9.08, $3.86, and $3.53. Vesting schedules include initial 25% cliffs and monthly vesting thereafter beginning on 09/18/2023 and a separate four-year monthly vesting from 04/01/2025.
Key dependencies are option exercise decisions and timing; dilution and insider alignment will materialize only if options are exercised. Monitor outstanding option counts and any subsequent Form 4s within the next 12 months for exercises or sales.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
Footnotes (1)
- The option has a vesting start date of September 18, 2023. The shares underlying the option vested with respect to 25% of the shares on the first anniversary of the vesting start date and vest as to the remainder in equal monthly installments on the 36 subsequent monthly anniversaries of the vesting start date. The shares underlying the option vested with respect to 25% of the shares on September 18, 2024 and vest as to the remainder in equal monthly installments on the 39 subsequent monthly anniversaries of December 18, 2023. The shares underlying the option vest in equal monthly installments over a period of four years commencing from April 1, 2025.
